A heart Watchman is a small, parachute-shaped implant about the size of a quarter that seals off a tiny pouch in the heart where dangerous blood clots tend to form. It’s designed for people with atrial fibrillation (AFib) who need an alternative to long-term blood thinners. Once the device is in place and healed, most patients can stop taking anticoagulant medications entirely.
Why the Device Exists
Atrial fibrillation causes the upper chambers of the heart to quiver instead of beating in a steady rhythm. When blood doesn’t move through the heart smoothly, it can pool and form clots. The most common site for these clots is a small, windsock-shaped pouch called the left atrial appendage (LAA), which sits off the upper left chamber. Over 95% of stroke-causing clots in AFib patients form in this one spot.
The standard treatment for this clot risk is blood-thinning medication, taken daily for life. But blood thinners carry their own risks, particularly serious bleeding. Some people have a history of major bleeds, are prone to falls, or simply can’t tolerate these drugs long-term. The Watchman device offers a physical solution: rather than thinning the blood to prevent clots, it blocks off the pouch where clots form in the first place.
How the Procedure Works
The implant is placed through a catheter-based procedure, similar to how a stent is inserted. You’re put under general anesthesia, so you’re asleep the entire time. The whole process takes about an hour.
A doctor makes a small puncture in the groin to access a blood vessel, then threads a thin, flexible catheter through that vessel and up into the heart’s left atrium. The Watchman device rides on the tip of the catheter. Once it reaches the left atrial appendage, the device opens like a small umbrella, pressing against the walls of the pouch to seal it off. The catheter is then carefully removed, and the groin incision is closed. Most patients go home the next day.
Who Qualifies for a Watchman
The FDA approved the Watchman for people with AFib who are at increased stroke risk and who have a valid reason to seek an alternative to lifelong blood thinners. To qualify for insurance coverage through Medicare, patients generally need a stroke risk score (called CHA₂DS₂-VASc) of 3 or higher, and they must be considered poor candidates for long-term anticoagulation while still being able to tolerate a short course of it after the procedure.
In practice, the most common reasons doctors cite for recommending the device are a history of major bleeding (about 64% of cases in a national registry), elevated stroke risk (65%), high fall risk (35%), and patient preference (34%). The typical patient has already experienced complications from blood thinners or faces conditions that make long-term use dangerous. Gastrointestinal bleeding is the most frequently reported bleeding event among people who receive the device, followed by prior brain bleeds.
Recovery and Medication After Implantation
Getting a Watchman doesn’t mean you stop blood thinners immediately. The device needs time for heart tissue to grow over it, creating a permanent seal. During this healing window, you’ll stay on a short course of anticoagulation, typically for about 45 days. After that, most patients switch to a combination of two milder blood-thinning drugs (an antiplatelet regimen) for roughly six months total, then transition to low-dose aspirin alone.
For patients with especially high bleeding risk, doctors may skip the initial anticoagulation period altogether and use only antiplatelet medications from the start. The exact plan depends on your individual risk profile.
Around 45 days after the procedure, you’ll undergo an imaging test, usually a transesophageal echocardiogram (a specialized ultrasound taken from inside the esophagus) or a cardiac CT scan. This check confirms the device is seated properly, no clots have formed on it, and there are no significant leaks around its edges. About 1% of patients show a clot on the device at this point, which is typically managed by extending the anticoagulation period. If imaging can’t be done at exactly 45 days, the risk of a problem is low, but follow-up imaging within the first year is still recommended.
How It Compares to Blood Thinners
A large network analysis published in the Journal of the American Heart Association found that the Watchman and newer blood thinners (like apixaban and rivarelbano) perform similarly overall for preventing stroke and systemic clots. Neither approach is clearly superior to the other in head-to-head comparisons.
Where the two approaches differ is in the type of protection they offer. Newer oral blood thinners are better at preventing the most common type of stroke, caused by a clot blocking blood flow to the brain. The Watchman, on the other hand, shows a strong advantage in reducing hemorrhagic stroke, the type caused by bleeding in the brain. In ranking analyses, the device had a 94% probability of being the best option for preventing hemorrhagic stroke and a 96% probability of being the best for reducing death from all causes compared to older blood thinners like warfarin.
The bleeding picture is nuanced. Overall bleeding rates look similar between the Watchman and newer blood thinners, but that includes the procedural bleeding that happens during and shortly after the implant surgery. Once you remove that early procedural window from the equation, the Watchman is associated with significantly less bleeding over time. This makes sense: you’re eliminating a daily medication that thins your blood everywhere in your body.
Long-Term Outcomes and Risks
Data from Medicare patients followed for five years after Watchman implantation shows that ischemic stroke occurs at a rate of roughly 1% to 1.5% per year, adding up to about 6.6% over five years. Hemorrhagic stroke is rare: under 1% over five years, with most cases occurring in the first six months.
Bleeding events are most common in the first year, particularly the first six months, when patients are still on some combination of blood-thinning medications. About 7.3% of patients experienced bleeding in year one. By five years, the cumulative rate reached 14.7%.
One number that stands out in the Medicare data is the five-year mortality rate of 44.2%. This sounds alarming, but context matters. Watchman recipients tend to be older adults with multiple serious health conditions, including the very bleeding problems and comorbidities that made them poor candidates for blood thinners in the first place. This mortality rate reflects the overall health of the population receiving the device, not necessarily the risk of the device itself.
Device Generations
The Watchman has gone through several iterations. The original model (Watchman 2.5) was followed by the Watchman FLX, which introduced a rounder, ball-shaped design that made it easier for doctors to position and deploy, with improved safety. The latest version, the Watchman FLX Pro, adds a coating designed to encourage heart tissue to grow over the device more quickly and comes in an expanded range of sizes, including a larger 40 mm option for patients with bigger appendages. These improvements have made the procedure more adaptable to different heart anatomies.